期刊
CANCER LETTERS
卷 332, 期 2, 页码 163-174出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.12.019
关键词
Apoptosis; CD95L; Death ligands; TNF; TRAIL
类别
资金
- Deutsche Forschungsgemeinschaft [DFG Wa 1025/18-1]
- Deutsche Krebshilfe [107554, 108267]
- Wilhelm Sander-Stiftung [2009.052.1]
CD95, TNFR1, TRAILR1 and TRAILR2 belong to a subgroup of TNF receptors which is characterized by a conserved cell death-inducing protein domain that connects these receptors to the apoptotic machinery of the cell. Activation of death receptors in malignant cells attracts increasing attention as a principle to fight cancer. Besides agonistic antibodies the major way to stimulate death receptors is the use of their naturally occurring death ligands CD95L, TNF and TRAIL However, dependent from the concept followed to develop a death ligand-based therapy various limiting aspects have to be taken into consideration on the way to a bedside usable drug. Problems arise in particular from the cell associated transmembrane nature of the death ligands, the poor serum half life of the soluble fragments derived from the transmembrane ligands, the ubiquitous expression of the death receptors and the existence of additional non-death receptors of the death ligands. Here, we summarize strategies how these limitations can be overcome by genetic engineering. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据